Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Nasus Pharma Announces FDA Clearance to Initiate Clinical Study of NS002 in the ...

14 September 2026 · By · Wire by Fusion42

Published

14 September 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at biospace.com →

◆ Verified

Fusion42 · 14 September 2026 · Fusion42 review

Nasus Pharma received FDA clearance to initiate a pivotal clinical study in Q4 2026 for NS002, an investigational intranasal epinephrine powder to treat anaphylaxis as a needle-free alternative to EpiPen. Topline data is expected in Q1 2027.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You have a rare chance to enter the $2 billion anaphylaxis treatment market with a needle-free option approved for trial. Getting ahead on regulatory milestones now opens patient and investor doors before injectables lose their dominance.

◆ Coverage

1 source · 14 Sep 2026

◆ Related on Wire

◆ Topics

Biotechfda-clearanceclinical-trialsanaphylaxisintranasal-deliveryneedle-freeepinephrine